Uncategorized
September 24, 2024 / September 24, 2024 by SFA Team
TEMPE, Ariz., Sept. 24, 2024 (GLOBE NEWSWIRE) — Nectero Medical, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, announced today that it received a 2024 AZBio™ Fast Lane Award from the Arizona Bioindustry Association (AZBio). Each year a select group of Arizona-based life science companies are recognized for the progress they are making […]
Read more »
April 11, 2024 / April 11, 2024 by SFA Team
The proceeds will support the execution of the Phase II/III trial and potential NDA submission for the Nectero EAST System, a Breakthrough Therapy for small to medium-sized AAA. TEMPE, Ariz.–(BUSINESS WIRE)–Nectero Medical, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease, today announced the closing of its $96 million Series D financing round. Financing […]
January 18, 2024 / January 18, 2024 by SFA Team
Trial to randomize 400 subjects at multiple sites, primarily in the U.S., to evaluate safety and efficacy of the investigational Nectero EAST System for treatment of infrarenal AAA, maximum diameter 3.5-5.0cm TEMPE, Ariz.–(BUSINESS WIRE)–Nectero Medical, a clinical-stage biotechnology company pioneering novel therapies to treat aneurysmal disease and improve patients’ lives, today announced initiation of a […]